Hikma Pharmaceuticals PLC (HKMPF) Stock Price & Analysis
Hikma Pharmaceuticals PLC (HKMPF) — price $22.00 (-6.72%), as of the Nov 19, 2026 trading session; market cap $4.55B.
Educational signal · not a buy or sell recommendation · How to read this
Hikma Pharmaceuticals PLC · HKMPF
Hikma Pharmaceuticals PLC is a global pharmaceutical company focused on developing, manufacturing, and commercializing a diverse portfolio of generic, branded, and injectable medications across multiple therapeutic areas. The firm maintains a significant presence in key markets including the UK, US, Europe, and the Middle East and North Africa region.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $22.00 | |
| Change on the day | -6.72% | |
| Market capitalisation | $4.55B | — |
| Price / earnings (trailing) | 12.35 | |
| Shares traded on the day | 4.4K |
Price & events
Other perspectives
Council score for Hikma Pharmaceuticals (HKMPF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Hikma Pharmaceuticals (HKMPF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Hikma Pharmaceuticals PLC (HKMPF) is the company analyzed here. It employs 9,500 people. In Q2 FY2026 it reported revenue of $1.70B and net income of $220M. The market values it at $4.55B.
What do the latest results show for Hikma Pharmaceuticals (HKMPF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.70B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.70B | $220M | $1.01 (diluted) |
| Q4 FY2025 | $1.70B | $165M | $0.74 (diluted) |
| Q2 FY2025 | $1.66B | $238M | $1.07 (diluted) |
| Q4 FY2024 | $1.56B | $133M | $0.60 (diluted) |
What are the financial strengths and risks for Hikma Pharmaceuticals (HKMPF)?
Short answer · as of
The distress and quality screens read Altman Z 2.73 · Piotroski F 6. Trailing ratios: ROE 15.0% · ROA 6.6% · current ratio 1.98 · earnings yield 8.3% · free-cash-flow yield 3.3%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held HKMPF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported HKMPF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: HKMPF Stock
These answers are editorial: 1 of these 8 answers is drawn from the HKMPF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is HKMPF a good stock to buy?
Stock Expert AI does not rate HKMPF buy, sell or hold. Hikma Pharmaceuticals PLC has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the HKMPF stock price today?
The last price recorded for Hikma Pharmaceuticals PLC (HKMPF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks associated with investing in HKMPF, particularly as an OTC stock?
Investing in HKMPF carries several risks, compounded by its status as an OTC 'Other' stock with an 'Unknown' disclosure status.
What are the key factors to evaluate for HKMPF?
Evaluate HKMPF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Deepening Penetration in the Injectables Market: Hikma's Injectables segment, which primarily supplies generic injectable medications to hospitals, represents a significant growth avenue. Not financial advice.
How frequently does HKMPF data refresh on this page?
HKMPF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven HKMPF's recent stock price performance?
Hikma Pharmaceuticals PLC (HKMPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established global presence and strong market share in the MENA region. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HKMPF overvalued or undervalued right now?
The trailing P/E of Hikma Pharmaceuticals PLC (HKMPF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HKMPF before investing?
Before investing in Hikma Pharmaceuticals PLC (HKMPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 9 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com